Detection of occult tumour cells in bone marrow and blood in breast cancer patients: Methods and clinical significance

Acta Oncologica

Volumn 35, Issue SUPPL. 8, 1996, Pages 13-18

  Kvalheim, Gunnar ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; BREAST CANCER; CANCER CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; OCCULT CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

BONE MARROW; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 0030425680     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098516     Document Type: Article

References (31)

1. Henderson IC, Canellos GP. Cancer of the breast. N Engl J Med 1980; 302: 17-30.
2. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy. Lancet 1992; 339: 1-15.
3. McGuire W, Abeloff MD, Fisher B, Glick JH, Henderson IC Osborne CK. Adjuvant therapy in node-negative breast cancer. Breast Cancer Res Treat 1989; 13: 97-115.
4. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative cancer patients with estrogen receptor-negative tumors: Eight-years' results from national surgery adjuvant breast and bowel project (NSABP) B-13 and first report of findings from NSABP-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14: 1982-92.
5. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82: 1006-15.
6. Gundersen S, Bøhler P, Hannisdal E, Høst H. Tumour size and histologic grading in node-negative breast cancer. Prognostic and therapeutic implications. Tidsskr Nor Lægeforen 1996; 116: 222-5.
7. Mansi JL, Easton D, Berger U, et al. Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years follow-up. Eur J Cancer 1991; 27: 1552-5.
8. Diel IJ, Kaufmann M, Costa SD, Bastert G. Monoclonal antibodies to detect breast cancer cells in bone marrow. In: DeVita VT, Hellman S, Rosenberg JB. eds. Important advances in oncology. Philadelphia: Lippincott Company, 1994: 143-64.
9. Schlimok G, Funke I, Holzmann B, et al. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 8672-6.
10. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991; 9: 1749-56.
11. Harbeck N, Untech M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-71.
12. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-6.
13. Moss TJ, Ross AA. The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematotherapy 1992; 1: 225-32.
14. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-5.
15. Pantel K, Schlimok G, Angstwurm M, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3: 165-73.
16. Naume B, Borgen E, Beiske K, et al. Detection of isolated breast cancer cells in peripheral blood or bone marrow by immunomagnetic techniques. J Hematother 1996; in press.
17. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-57.
18. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-82.
19. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-76.
20. Krismann M, Todt B, Schröder J, et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13: 2769-75.
21. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 1995; 159: 43-7.
22. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994; 12: 725-9.
23. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-10.
24. Sharp JG, Mann SL, Murphy B, Weekes C. Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: A review. J Hematother 1995; 4: 141-8.
25. Kvalheim G, Ugland K, Erikstein B, et al. Detection of micrometastasis in bone marrow and blood in high-risk stage II breast cancer patients (abstract). First International Symposium on Minimal Residual Cancer 1996; 3: 21.
26. Kvalheim G, Wang MY, Pharo A, et al. Purging of tumor cells from leukapheresis products: Experimental and clinical aspects. J Hematother 1996; 5: 427-36.
27. Schlimok K, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmuller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 1995; 11: 1799-803.
28. Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother 1994; 3: 315-22.
29. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. JNCI 1993; 17: 1419-23.
30. + cells. Leukemia 1992; 6: 845-52.
31. Fodstad Ø, Hoøifødt H, Rye PD, Trones GE, Beiske K. New immunobead techniques for sensitive detection of malignant cells in blood and bone marrow. Proceedings of the American Association for Cancer Research (abstract) 1996; 37: 217.